PCM
TNGX icon

Penserra Capital Management’s Tango Therapeutics TNGX Stock Holding History

Penserra Capital Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,501
Closed -$11K – 1210
2022
Q2 		$11K Buy
2,501
+42
+2% +$254 ﹤0.01% 1233
2022
Q1 		$18K Buy
2,459
+51
+2% +$442 ﹤0.01% 1289
2021
Q4 		$26K Sell
2,408
-7,936
-77% -$95.4K ﹤0.01% 1196
2021
Q3 		$133K Buy
+10,344
New +$124K ﹤0.01% 703

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Penserra Capital Management's TNGX Position: Q3 2022 in Review

Penserra Capital Management sold out of Tango Therapeutics (TNGX) in Q3 2022, closing a stake of 2,501 shares — an estimated $11K sold.

Penserra Capital Management first reported a position in TNGX in Q3 2021 and held it in 4 quarters. The position peaked at $133K in Q3 2021. 87 funds tracked by Wall St. Rank hold TNGX as of Q3 2022.

  • Penserra Capital Management reported no remaining Tango Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 2,501 Tango Therapeutics shares in Q3 2022, an estimated $11K.
  • Penserra Capital Management first reported a position in Tango Therapeutics in Q3 2021 and held it in 4 quarters.
  • Penserra Capital Management's Tango Therapeutics position peaked at $133K in Q3 2021.
  • 87 funds tracked by Wall St. Rank held Tango Therapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.